ORGO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ORGO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Organogenesis Holdings's change in receivables for the quarter that ended in Jun. 2024 was $-10.9 Mil. It means Organogenesis Holdings's Accounts Receivable increased by $10.9 Mil from Mar. 2024 to Jun. 2024 .
Organogenesis Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was $5.5 Mil. It means Organogenesis Holdings's Accounts Receivable declined by $5.5 Mil from Dec. 2022 to Dec. 2023 .
Organogenesis Holdings's Accounts Receivable for the quarter that ended in Jun. 2024 was $105.9 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Organogenesis Holdings's Days Sales Outstanding for the three months ended in Jun. 2024 was 74.23.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Organogenesis Holdings's liquidation value for the three months ended in Jun. 2024 was $3.1 Mil.
The historical data trend for Organogenesis Holdings's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Change In Receivables | Get a 7-Day Free Trial | -4.69 | -17.57 | -28.65 | -8.77 | 5.54 |
Organogenesis Holdings Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Change In Receivables | Get a 7-Day Free Trial | -1.54 | 3.21 | 7.30 | -15.12 | -10.86 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (NAS:ORGO) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Organogenesis Holdings's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 105.945 | / | 130.234 | * | 91 |
= | 74.23 |
2. In Ben Graham's calculation of liquidation value, Organogenesis Holdings's accounts receivable are only considered to be worth 75% of book value:
Organogenesis Holdings's liquidation value for the quarter that ended in Jun. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 89.902 | - | 179.662 | + | 0.75 * 105.945 | + | 0.5 * 26.883 |
= | 3.1 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Organogenesis Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Albert Erani | 10 percent owner | 150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002 |
Michael W Katz | 10 percent owner | |
Arthur S Leibowitz | director | 139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050 |
Michael Joseph Driscoll | director | C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021 |
Gary S. Gillheeney | director, officer: President and CEO | C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021 |
Gilberto Quintero | director | C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021 |
Michele Ilene Korfin | director | 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004 |
Antonio S. Montecalvo | officer: VP Health Policy & Contracting | C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021 |
Jon L Giacomin | director | 7000 CARDINAL PLACE, DUBLIN OH 43017 |
David Francisco | officer: Chief Financial Officer | C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021 |
Red Holdings, Llc | 10 percent owner | C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021 |
Prathyusha Duraibabu | director | C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804 |
Glenn H Nussdorf | director, 10 percent owner | |
Alan A. Ades | director, 10 percent owner | C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021 |
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016 | 10 percent owner | C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021 |
From GuruFocus
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 05-02-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 04-16-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 08-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.